13.86
前日終値:
$14.02
開ける:
$13.89
24時間の取引高:
220.05K
Relative Volume:
0.10
時価総額:
$1.66B
収益:
$59.61M
当期純損益:
$-262.14M
株価収益率:
-3.5357
EPS:
-3.92
ネットキャッシュフロー:
$-247.49M
1週間 パフォーマンス:
-3.42%
1か月 パフォーマンス:
+6.13%
6か月 パフォーマンス:
-0.65%
1年 パフォーマンス:
+44.77%
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
名前
Arcutis Biotherapeutics Inc
セクター
電話
805-418-5006
住所
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ARQT
Arcutis Biotherapeutics Inc
|
13.83 | 1.66B | 59.61M | -262.14M | -247.49M | -3.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.36 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
533.65 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
321.19 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
558.44 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
242.58 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-30 | 開始されました | H.C. Wainwright | Buy |
2024-08-28 | 開始されました | Jefferies | Buy |
2024-01-03 | アップグレード | Mizuho | Neutral → Buy |
2023-10-26 | ダウングレード | Mizuho | Buy → Neutral |
2023-10-13 | ダウングレード | Goldman | Buy → Neutral |
2022-09-07 | 開始されました | Needham | Buy |
2022-03-17 | 開始されました | Goldman | Buy |
2021-06-30 | 開始されました | Mizuho | Buy |
2021-05-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-11-09 | アップグレード | Goldman | Neutral → Buy |
2020-10-08 | 開始されました | Truist | Buy |
2020-02-25 | 開始されました | Cantor Fitzgerald | Overweight |
2020-02-25 | 開始されました | Cowen | Outperform |
2020-02-25 | 開始されました | Goldman | Neutral |
2020-02-25 | 開始されました | Guggenheim | Buy |
すべてを表示
Arcutis Biotherapeutics Inc (ARQT) 最新ニュース
When (ARQT) Moves Investors should Listen - news.stocktradersdaily.com
Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials - MSN
Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks
Arcutis: Out Of The Woods, Ready For Commercialization - Seeking Alpha
10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis - Yahoo Finance
Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com South Africa
Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Australia
Arcutis Biotherapeutics (ARQT) Begins Trial for Infant Atopic De - GuruFocus
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis - Taiwan News
Arcutis says Zoryve data demonstrates durable atopic dermatitis improvements - MSN
H.C. Wainwright maintains $19 target on Arcutis stock - Investing.com Australia
H.C. Wainwright maintains $19 target on Arcutis stock By Investing.com - Investing.com South Africa
Wellington Management Group LLP Sells 3,882 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq L - GuruFocus
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ARQT Stock News - GuruFocus
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Arcutis Grants 72,000 Restricted Stock Units to 9 New Hires: Key Details on 4-Year Vesting Plan - Stock Titan
Arcutis Presents Long-Term INTEGUMENT-OLE Data on Roflumilast at RAD 2025 - Dermatology Times
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis - Benzinga
Road to RAD: What to Expect - Dermatology Times
ARQT Reveals Promising Long-Term Data for Zoryve in Atopic Derma - GuruFocus
Arcutis Biotherapeutics director Heron buys $30,246 in stock By Investing.com - Investing.com India
Arcutis Biotherapeutics director Heron buys $30,246 in stock - Investing.com Australia
Where are the Opportunities in (ARQT) - news.stocktradersdaily.com
Arcutis (ARQT) to Showcase New Data at 2025 RAD Conference | ARQ - GuruFocus
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast - GuruFocus
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference - The Manila Times
Arcutis (ARQT) to Showcase New Data at 2025 RAD Conference | ARQT Stock News - GuruFocus
New Clinical Data: ZORYVE's Breakthrough 34-Week Skin Control for Children with Atopic Dermatitis - Stock Titan
Two Sigma Investments LP Cuts Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside - Seeking Alpha
H.C. Wainwright reiterates buy rating and $19 target on Arcutis stock - Investing.com
Transcript : Arcutis Biotherapeutics, Inc.Shareholder/Analyst Call - marketscreener.com
Nuveen Asset Management LLC Has $5.11 Million Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 5% – Time to Sell? - Defense World
Possible Bearish Signals With Arcutis Biotherapeutics Insiders Disposing Stock - simplywall.st
Ameriprise Financial Inc. Acquires 50,662 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Biotherapeutics SVP sells $24,806 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics SVP sells $24,806 in stock - Investing.com Australia
Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Immuno-Dermatology Leader Arcutis Set for Key Goldman Sachs Healthcare Conference Presentation - Stock Titan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Bank of America Corp DE - Defense World
Needham & Company LLC Reaffirms Buy Rating for Arcutis Biotherapeutics (NASDAQ:ARQT) - Defense World
Arcutis wins FDA nod for Zoryve foam for plaque psoriasis - MSN
Analyst Expectations For Arcutis Biotherapeutics's Future - Benzinga
ARQT Analyst Reiterates Buy Rating with $20 Price Target | ARQT Stock News - GuruFocus
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - BioSpace
Arcutis Biotherapeutics Inc (ARQT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):